Trials / Completed
CompletedNCT00122356
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Barwon Health · Other Government
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long alendronate treatment is needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alendronate sodium | 70mg tablets, once weekly |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2013-02-01
- Completion
- 2013-03-01
- First posted
- 2005-07-22
- Last updated
- 2013-03-13
Locations
8 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00122356. Inclusion in this directory is not an endorsement.